Expert Interview
Digging into EyePoint Pharma's recent phase 1 data on its anti-VEGF candidate, EYP-1901 in macular edema and wet-AMD
Ticker(s): EYPT, REGNInstitution: Retina Consultants of Southern CA
- Ophthalmologist in private practice & Clinical Faculty at Loma Linda University and the Loma Linda Veterans Affairs Hospital; competed surgical vitreoretinal fellowship at the University of Iowa.
- Treats 750 patients with Macular Edema
- Specializes in all aspects of vitreoretinal medicine and surgery, as well as uveitis and ocular tumors; has numerous publications in major ophthalmic journals and textbooks.
Please describe your background and current practice setting
Added By: ben_adminHow many patients with macular edema do you currently treat monthly?
Added By: ben_adminCan you break down your treatment algorithm? What are you using in the first and second line for these indications?
Added By: ben_adminWhat were your overall impressions of Eyepoint's phase 1 data for treatment of patients with wet-AMD?
Added By: ben_adminPlease rank for excitement for Eyepoint's EYP-1901 medication on a scale of 1-10
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
